Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment

Xanthine oxidoreductase (XOR) is an enzyme that catalyzes hypoxanthine and xanthine to xanthine and uric acid, respectively. Plasma XOR activity has recently been measured in humans. However, limited information is known about plasma XOR activity in patients with type 2 diabetes mellitus, and its changes after short‐term glycemic control treatment.

[1]  F. Hu,et al.  Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. , 2019, The lancet. Diabetes & endocrinology.

[2]  K. Shimamoto,et al.  Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight. , 2019, Endocrine journal.

[3]  J. Borén,et al.  Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[4]  G. Homanics,et al.  Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities , 2019, Diabetes.

[5]  B. Zinman,et al.  Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial , 2018, Diabetologia.

[6]  S. Okamoto,et al.  Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study , 2018, Journal of diabetes investigation.

[7]  K. Shimamoto,et al.  Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[8]  E. Fukusaki,et al.  Hypoxanthine Secretion from Human Adipose Tissue and its Increase in Hypoxia , 2018, Obesity.

[9]  Dongli Tian,et al.  Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials , 2018, Diabetes, obesity & metabolism.

[10]  Y. Moriwaki,et al.  Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans. , 2017, Metabolism: clinical and experimental.

[11]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[12]  M. Oka,et al.  A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  Yingying Ding,et al.  Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.

[14]  E. Kelley.  A new paradigm for XOR-catalyzed reactive species generation in the endothelium , 2015, Pharmacological reports : PR.

[15]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[16]  L. Polito,et al.  Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. , 2014, Atherosclerosis.

[17]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[18]  L. Polito,et al.  Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. , 2014, Biochimica et biophysica acta.

[19]  M. Al-mallah,et al.  A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.

[20]  T. Funahashi,et al.  Uric Acid Secretion from Adipose Tissue and Its Increase in Obesity* , 2013, The Journal of Biological Chemistry.

[21]  L. Dimeglio,et al.  Type 1 Diabetes , 2019, Epidemiology of Diabetes.

[22]  H. Kaneto,et al.  Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. , 2009, Atherosclerosis.

[23]  大坪 俊夫.  Xanthine oxidoreductase 遺伝子欠損マウスの解析 , 2008 .

[24]  J. Hare,et al.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.

[25]  H. J. Frank.  The Authors , 2002, Gov. Inf. Q..

[26]  A. Meneshian,et al.  The Physiology of Endothelial Xanthine Oxidase: From Urate Catabolism to Reperfusion Injury to Inflammatory Signal Transduction , 2002, Microcirculation.

[27]  S. Marklund,et al.  Binding of Xanthine Oxidase to Vascular Endothelium , 1999, The Journal of Biological Chemistry.

[28]  P. Hassoun,et al.  Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury. , 1998, American journal of respiratory and critical care medicine.

[29]  M. Calzi,et al.  Tissue- and cell-specific expression of mouse xanthine oxidoreductase gene in vivo: regulation by bacterial lipopolysaccharide. , 1995, The Biochemical journal.

[30]  K. Hirano,et al.  Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. , 1993, The Biochemical journal.

[31]  J. Gollan,et al.  Enhanced activity of the free radical producing enzyme xanthine oxidase in hypoxic rat liver. Regulation and pathophysiologic significance. , 1991, The Journal of clinical investigation.

[32]  H. P. Jones,et al.  Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. , 1987, The Journal of clinical investigation.

[33]  H. Tomita,et al.  Establishment of the Process in Blood Sampling and Sample Handling as a Biomarker of Hypoxia-Inducible Diseases; Plasma Hypoxanthine and Xanthine Measurement , 2018 .

[34]  J. Ampuero,et al.  Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. , 2015, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[35]  [Evidence-based practice guideline for the treatment of CKD]. , 2009, Nihon Jinzo Gakkai shi.

[36]  S. Yamashita,et al.  Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. , 1986, International journal of obesity.